Biosimilars Will Get PDUFA-Style Reviews Under New User Fee Plan

28 Sep 2016

FDA will have a total of 12 months to review 351(k) applications and additional time to schedule certain product development meetings under the Biosimilar User Fee Act II agreement; measures to enhance management of user fee resources and improve hiring will carry over from PDUFA VI.

FDA and industry found much to like in the Prescription Drug User Fee Act (PDUFA) program that they thought worthy of extending to biosimilar reviews, despite wanting to separate the biosimilar program from the financial constraints of its older sibling.

One of the biggest regulatory process changes proposed for the second iteration of the Biosimilar User Fee Act (BsUFA) is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

EU Biosimilar Filings, Opinions And Approvals

06 Aug 2025

• By Neena Brizmohun

A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.

Court Allows MSN Marketing Of Entresto Generic, But More Legal Issues Pending

04 Aug 2025

• By Dean Rudge

Novartis failed to stop MSN from launching a generic Entresto and saw an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.

Generic Drugs And AI: Maximum Daily Dose Tool Could Help US FDA Be ‘At The Forefront’

01 Aug 2025

• By Michael McCaughan

The FDA is testing a new artificial intelligence tool to help generic drug developers automate maximum daily dose calculations.